Item 3.03 Material Modification to Rights of Security Holders.
On December 24, 2020, Wize Pharma, Inc. (the "Company") entered into an
agreement (the "Agreement") with certain holders (the "Holders") representing a
majority of the Series A common stock purchase warrants issued by the Company in
October 2018 (the "Warrants"). Pursuant to the terms of the Agreement, the
Company and Holders mutually agreed that the Company would voluntarily reduce
the exercise price of the Warrants to $0.001 per share until January 7, 2021,
after which such exercise price shall revert back to $0.16 per share.
As a result of the adjustment to the exercise price of the Warrants, the
exercise price of the warrants issued in November 2017 (the "2017 Warrants"),
the placement agent warrants issued in October 2018 (the "2018 Placement Agent
Warrants"), the warrants issued to certain lenders in May 2019 (the "May 2019
Warrants"), the warrants issued to certain lenders in November 2019 (the
"November 2019 Warrants"), the warrants issued to certain purchasers from the
private placement in December 2019 (the "December 2019 Warrants") and certain
investment rights issued on January 2017 (the "Investment Rights") were also
adjusted to reflect a reduced exercise price of $0.001 per share (collectively,
the "Warrant Adjustments"). As a result of the Warrant Adjustments, on December
29, 2020 an aggregate of 13,332,657 were issued as a result of the exercise of
such warrants, each on a cashless basis. Such warrant exercises also included
warrants beneficially owned by our Chief Executive Officer, Noam Dannenberg.
1© Edgar Online, source Glimpses
WIZE PHARMA, INC. 
